Singapore markets closed

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9708+0.0708 (+3.73%)
As of 02:47PM EDT. Market open.

GeoVax Labs, Inc.

1900 Lake Park Drive
Suite 380
Smyrna, GA 30080
United States
678 384 7220
https://www.geovax.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees17

Key executives

NameTitlePayExercisedYear born
Mr. David Alan DoddChairman, President & CEO384.2kN/A1950
Dr. Mark J. Newman Ph.D.Chief Scientific Officer291.5kN/A1955
Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Medical Officer361.03kN/A1951
Dr. Harriet Latham Robinson Ph.D.Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory BoardN/AN/A1938
Mr. Mark W. Reynolds CPACFO & Corporate Secretary348.2kN/A1962
Jeffrey WelchHead of Process Development & Manufacturing OperationsN/AN/AN/A
Dr. John W. Sharkey Ph.D.Vice President of Business DevelopmentN/AN/A1956
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Corporate governance

GeoVax Labs, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.